NANOBIOTIX has completed the dose escalation phase of a Phase 1 study evaluating NBTXR3, a potential first-in-class radioenhancer.

Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002)

A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects.

In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.

Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.

Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.

Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma

This innovative vaccine, developed by CureVac, is multivalent and contains antigens that match the four flu strains recommended by the World Health Organization (WHO).

Eilean Therapeutics LLC has received approval from the Human Research Ethics Committee in Australia to commence a Phase I clinical trial for lomonitinib (ZE46-0134).

A recent Phase 1b clinical trial of topical pravibismane for managing moderate to severe diabetic foot ulcers has shown promising results.

TPST-1120, a novel oral PPAR⍺ inhibitor, has shown promising results in treating cancers that are resistant to PD-1 inhibitors and those with weakened immune systems.

LOTIS-7 Phase 1b Trial Completes Dose Escalation: ZYNLONTA® and Bispecific Antibodies for Non-Hodgkin Lymphoma Patients, No Severe Side Effects Observed.